Complicações mais prevalentes no uso de soluções hiperosmolares no manejo da Hipertensão Intracraniana
##plugins.themes.bootstrap3.article.sidebar##
Publicado
Oct 19, 2023
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Comparar as complicações mais prevalentes no uso de soluções hiperosmolares (manitol e solução salinos hipertônicos (SSH)) no manejo da hipertensão intracraniana (HIC). Revisão bibliográfica: A pressão intracraniana (PIC) elevada é um preditor importante da deterioração neurológica e muitos estudos têm comparado a eficácia de terapias hiperosmolares no controle da hipertensão craniana, sendo as mais estudadas a solução salina hipertônica e o manitol. O presente artigo aborda as intercorrências dessas duas soluções durante suas administrações no manejo da HIC, de modo a constatar se uma delas possui menor efeito adverso em relação à outra e se existem situações específicas nas quais o uso de cada uma se adequa melhor. Considerações finais: Observa-se que, além dos benefícios semelhantes documentados na literatura acerca do uso do manitol e da SSH no manejo da HIC, também se tem as complicações similares como LRA e o efeito rebote. Nesse sentido, o presente estudo visa comparar as intercorrências em comum e as demais com o objetivo de esclarecer uma análise detalhada destes efeitos para escolha do agente e manejo mais eficaz dos pacientes.
##plugins.themes.bootstrap3.article.details##
Como Citar
QueirozJ. G. V. de, MussiH. G., SilveiraA. I. C., LimaG. F., RodríguezI. S. T., SantosJ. P. R., OliveiraL. F., BarbaraL. X. S., CerceauM. P. B., & CunhaM. V. R. da. (2023). Complicações mais prevalentes no uso de soluções hiperosmolares no manejo da Hipertensão Intracraniana. Revista Eletrônica Acervo Saúde, 23(10), e14395. https://doi.org/10.25248/reas.e14395.2023
Seção
Revisão Bibliográfica
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
1. BENSON JC, et al. The Monro-Kellie Doctrine: A Review and Call for Revision. American Journal of Neuroradiology. 2023; 44(1): 2-6.
2. COOK AM, et al. Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients. Neurocrit Care. 2020; 32(3): 647-666.
3. CHEN H, et al. Hypertonic saline versus other intracranial pressure-lowering agents for people with acute traumatic brain injury. Cochrane Database Syst Rev. 2019; 12(12): CD010904.
4. CHESANI FH, et al. O uso dos critérios de diagnóstico da síndrome do desconforto respiratório agudo por profissionais da saúde para pacientes internados em UTI: um estudo observacional utilizando a técnica de análise de conteúdo. Rev. Assoc. Méd. Rio Gd. do Sul. 2019; 4: 65.
5. DEVEAU RF Jr, et al. Safety of peripherally administered 3% hypertonic saline. Am J Emerg Med. 2023; 63: 127-131.
6. ERDMAN MJ,et al. Predictors of Acute Kidney Injury in Neurocritical Care Patients Receiving Continuous Hypertonic Saline. Neurohospitalist. 2017; 7(1): 9-14.
7. FANG J, et al. Comparison of equiosmolar hypertonic saline and mannitol for brain relaxation during craniotomies: A meta-analysis of randomized controlled trials. Neurosurg Rev. 2018; 41(4): 945-956.
8. FLORIDO LMP, et al. Hipertensão intracraniana no TCE: Solução salina hipertônica vs. Manitol. Revista Caderno de Medicina. 2019; 2(3): 5-12.
9. FURQUIM JD, et al. Manejo da hipertensão intracraniana no trauma cranioencefálico pediátrico. Residência Pediatrica. 2022; 12(3): 632-640.
10. GONDIM FAA, et al. Osmolality not predictive of mannitol-induced acute renal insufficiency. J Neurosurg. 2005; 103(3): 444-7.
11. GU J, et al. Hypertonic saline or mannitol for treating elevated intracranial pressure in traumatic brain injury: a meta-analysis of randomized controlled trials. Neurosurg Rev. 2019; 42: 499–509.
12. GONDA DD, et al. Complications associated with prolonged hypertonic saline therapy in children with elevated intracranial pressure. Pediatr Crit Care Med. 2013; 14(6): 610-20.
13. HALSTEAD MR, GEOCADIN RG. The Medical Management of Cerebral Edema: Past, Present, and Future Therapies. Neurotherapeutics. 2019; 16(4): 1133-1148.
14. HUANG X, et al. Equimolar doses of hypertonic agents (saline or mannitol) in the treatment of intracranial hypertension after severe traumatic brain injury. Medicine (Baltimore). 2020; 99(38): e22004.
15. JAGANNATHA AT, et al. An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. J Clin Neurosci. 2016; 27: 68-73.
16. JANNOTTA GE, et al. Administration of 3% Sodium Chloride Through Peripheral Intravenous Access: Development and Implementation of a Protocol for Clinical Practice. Worldviews Evid Based Nurs. 2021; 18(2): 147-153.
17. MANGAT HS. Hypertonic saline infusion for treating intracranial hypertension after severe traumatic brain injury. Crit Care. 2018; 22(1): 37.
18. MANGAT HS, et al. Hypertonic Saline is Superior to Mannitol for the Combined Effect on Intracranial Pressure and Cerebral Perfusion Pressure Burdens in Patients With Severe Traumatic Brain Injury. Neurosurgery. 2020; 86(2): 221-230.
19. MIYOSHI Y, et al. Effects of hypertonic saline versus mannitol in patients with traumatic brain injury in prehospital, emergency department, and intensive care unit settings: a systematic review and meta-analysis. j intensive care. 2020; 8: 61.
20. MUSSI HG, et al. Métodos não invasivos para monitorização da pressão intracraniana: uma revisão atual. Revista Eletrônica Acervo Saúde. 2023. 23(1): e11450.
21. PEREZ CA, FIGUEROA SA. Complication Rates of 3% Hypertonic Saline Infusion Through Peripheral Intravenous Access. Journal of Neuroscience Nursing, 2017; 49(3):191-195.
22. POOLE D, et al. Evidence for Mannitol as an Effective Agent Against Intracranial Hypertension: An Individual Patient Data Meta-analysis. Neurocrit Care. 2020; 32(1): 252-261.
23. RAY PK, et al. Study of changes in cardiac output, stroke volume, and cardiac index with two doses of mannitol infusion during supratentorial craniotomy. Ain-Shams J Anesthesiol. 2022; 14: 94-101.
24. ROQUILLY A, et al. Effect of Continuous Infusion of Hypertonic Saline vs Standard Care on 6-Month Neurological Outcomes in Patients With Traumatic Brain Injury: The COBI Randomized Clinical Trial. JAMA. 2021; 325(20): 2056-2066.
25. SEO H, et al. A prospective randomized trial of the optimal dose of mannitol for intraoperative brain relaxation in patients undergoing craniotomy for supratentorial brain tumor resection. J Neurosurg. 2017; 126(6): 1839-1846.
26. SHI J, et al. Hypertonic saline and mannitol in patients with traumatic brain injury: A systematic and meta-analysis. Medicine (Baltimore). 2020; 99(35): e21655.
27. SU Y, et al. Comparison of equiosmolar doses of 10% hypertonic saline and 20% mannitol for controlling intracranial hypertention in patients with large hemispheric infarction. Clin Neurol Neurosurg. 2021; 200: 106359.
28. TSAOUSI G, et al. Cardiac output changes after osmotic therapy in neurosurgical and neurocritical care patients: a systematic review of the clinical literature. Br J Clin Pharmacol. 2018; 84(4): 636-648.
29. WEBSTER DL, et al. Higher-volume hypertonic saline and increased thrombotic risk in pediatric traumatic brain injury. J Crit Care. 2015; 30(6): 1267-71.
30. WIÓREK A, et al. Hyperosmolar Treatment for Patients at Risk for Increased Intracranial Pressure: A Single-Center Cohort Study. Int J Environ Res Public Health. 2020; 17(12): 4573.
31. WITHERSPOON B, ASHBY NE. The Use of Mannitol and Hypertonic Saline Therapies in Patients with Elevated Intracranial Pressure: A Review of the Evidence. Nurs Clin North Am. 2017; 52(2): 249-260.
32. ZHANG W, et al. Mannitol in Critical Care and Surgery Over 50+ Years: A Systematic Review of Randomized Controlled Trials and Complications With Meta-Analysis. J Neurosurg Anesthesiol. 2019; 31(3): 273-284.
2. COOK AM, et al. Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients. Neurocrit Care. 2020; 32(3): 647-666.
3. CHEN H, et al. Hypertonic saline versus other intracranial pressure-lowering agents for people with acute traumatic brain injury. Cochrane Database Syst Rev. 2019; 12(12): CD010904.
4. CHESANI FH, et al. O uso dos critérios de diagnóstico da síndrome do desconforto respiratório agudo por profissionais da saúde para pacientes internados em UTI: um estudo observacional utilizando a técnica de análise de conteúdo. Rev. Assoc. Méd. Rio Gd. do Sul. 2019; 4: 65.
5. DEVEAU RF Jr, et al. Safety of peripherally administered 3% hypertonic saline. Am J Emerg Med. 2023; 63: 127-131.
6. ERDMAN MJ,et al. Predictors of Acute Kidney Injury in Neurocritical Care Patients Receiving Continuous Hypertonic Saline. Neurohospitalist. 2017; 7(1): 9-14.
7. FANG J, et al. Comparison of equiosmolar hypertonic saline and mannitol for brain relaxation during craniotomies: A meta-analysis of randomized controlled trials. Neurosurg Rev. 2018; 41(4): 945-956.
8. FLORIDO LMP, et al. Hipertensão intracraniana no TCE: Solução salina hipertônica vs. Manitol. Revista Caderno de Medicina. 2019; 2(3): 5-12.
9. FURQUIM JD, et al. Manejo da hipertensão intracraniana no trauma cranioencefálico pediátrico. Residência Pediatrica. 2022; 12(3): 632-640.
10. GONDIM FAA, et al. Osmolality not predictive of mannitol-induced acute renal insufficiency. J Neurosurg. 2005; 103(3): 444-7.
11. GU J, et al. Hypertonic saline or mannitol for treating elevated intracranial pressure in traumatic brain injury: a meta-analysis of randomized controlled trials. Neurosurg Rev. 2019; 42: 499–509.
12. GONDA DD, et al. Complications associated with prolonged hypertonic saline therapy in children with elevated intracranial pressure. Pediatr Crit Care Med. 2013; 14(6): 610-20.
13. HALSTEAD MR, GEOCADIN RG. The Medical Management of Cerebral Edema: Past, Present, and Future Therapies. Neurotherapeutics. 2019; 16(4): 1133-1148.
14. HUANG X, et al. Equimolar doses of hypertonic agents (saline or mannitol) in the treatment of intracranial hypertension after severe traumatic brain injury. Medicine (Baltimore). 2020; 99(38): e22004.
15. JAGANNATHA AT, et al. An equiosmolar study on early intracranial physiology and long term outcome in severe traumatic brain injury comparing mannitol and hypertonic saline. J Clin Neurosci. 2016; 27: 68-73.
16. JANNOTTA GE, et al. Administration of 3% Sodium Chloride Through Peripheral Intravenous Access: Development and Implementation of a Protocol for Clinical Practice. Worldviews Evid Based Nurs. 2021; 18(2): 147-153.
17. MANGAT HS. Hypertonic saline infusion for treating intracranial hypertension after severe traumatic brain injury. Crit Care. 2018; 22(1): 37.
18. MANGAT HS, et al. Hypertonic Saline is Superior to Mannitol for the Combined Effect on Intracranial Pressure and Cerebral Perfusion Pressure Burdens in Patients With Severe Traumatic Brain Injury. Neurosurgery. 2020; 86(2): 221-230.
19. MIYOSHI Y, et al. Effects of hypertonic saline versus mannitol in patients with traumatic brain injury in prehospital, emergency department, and intensive care unit settings: a systematic review and meta-analysis. j intensive care. 2020; 8: 61.
20. MUSSI HG, et al. Métodos não invasivos para monitorização da pressão intracraniana: uma revisão atual. Revista Eletrônica Acervo Saúde. 2023. 23(1): e11450.
21. PEREZ CA, FIGUEROA SA. Complication Rates of 3% Hypertonic Saline Infusion Through Peripheral Intravenous Access. Journal of Neuroscience Nursing, 2017; 49(3):191-195.
22. POOLE D, et al. Evidence for Mannitol as an Effective Agent Against Intracranial Hypertension: An Individual Patient Data Meta-analysis. Neurocrit Care. 2020; 32(1): 252-261.
23. RAY PK, et al. Study of changes in cardiac output, stroke volume, and cardiac index with two doses of mannitol infusion during supratentorial craniotomy. Ain-Shams J Anesthesiol. 2022; 14: 94-101.
24. ROQUILLY A, et al. Effect of Continuous Infusion of Hypertonic Saline vs Standard Care on 6-Month Neurological Outcomes in Patients With Traumatic Brain Injury: The COBI Randomized Clinical Trial. JAMA. 2021; 325(20): 2056-2066.
25. SEO H, et al. A prospective randomized trial of the optimal dose of mannitol for intraoperative brain relaxation in patients undergoing craniotomy for supratentorial brain tumor resection. J Neurosurg. 2017; 126(6): 1839-1846.
26. SHI J, et al. Hypertonic saline and mannitol in patients with traumatic brain injury: A systematic and meta-analysis. Medicine (Baltimore). 2020; 99(35): e21655.
27. SU Y, et al. Comparison of equiosmolar doses of 10% hypertonic saline and 20% mannitol for controlling intracranial hypertention in patients with large hemispheric infarction. Clin Neurol Neurosurg. 2021; 200: 106359.
28. TSAOUSI G, et al. Cardiac output changes after osmotic therapy in neurosurgical and neurocritical care patients: a systematic review of the clinical literature. Br J Clin Pharmacol. 2018; 84(4): 636-648.
29. WEBSTER DL, et al. Higher-volume hypertonic saline and increased thrombotic risk in pediatric traumatic brain injury. J Crit Care. 2015; 30(6): 1267-71.
30. WIÓREK A, et al. Hyperosmolar Treatment for Patients at Risk for Increased Intracranial Pressure: A Single-Center Cohort Study. Int J Environ Res Public Health. 2020; 17(12): 4573.
31. WITHERSPOON B, ASHBY NE. The Use of Mannitol and Hypertonic Saline Therapies in Patients with Elevated Intracranial Pressure: A Review of the Evidence. Nurs Clin North Am. 2017; 52(2): 249-260.
32. ZHANG W, et al. Mannitol in Critical Care and Surgery Over 50+ Years: A Systematic Review of Randomized Controlled Trials and Complications With Meta-Analysis. J Neurosurg Anesthesiol. 2019; 31(3): 273-284.